Thalidomide for the treatment of angiodysplasia‐related recurrent gastrointestinal hemorrhage: Is low dose a safe and viable option?

Thalidomide for the treatment of angiodysplasia‐related recurrent gastrointestinal hemorrhage: Is low dose a safe and viable option?

Abstract Thalidomide is often used for the management of refractory gastrointestinal angiodysplasia (GIAD). The tolerance, toxic profile, and compliance of thalidomide are dose‐dependent. The low‐dose thalidomide (50 mg) is safe and a viable option for bleeding related to GIAD.

Bibliographic Details
Main Authors: Harish Patel, Shehriyar Mehershahi, Danial Haris Shaikh, Jasbir Makker, Sureshkumar Nayudu, Prospere Remy, Sridhar Chilimuri
Format: Article
Language:English
Published: Wiley 2019-12-01
Series:Clinical Case Reports
Subjects:
angiodyslasia and pharmacological management
angiodysplasia and thalidomide
low‐dose thalidomide and GI bleed
thalidomide and small bowel AVM
Online Access:https://doi.org/10.1002/ccr3.2501

Similar Items

Similar Items